Home/ Supplements/ Iron/ Ferrex 150

Ferrex 150

product on market Capsule Breckenridge Pharmaceutical Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • Limited research evidence available for ingredients
B Label Compliance Grade
Label

Product Label

Label for Ferrex 150
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Capsule(s)
Serving Size
100
Servings
Mineral
Product Type
0%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Iron
150 mg (833% DV)

Other Ingredients

Sodium Lauryl Sulfate Gelatin Stearic Acid Polyethylene Glycol Microcrystalline Cellulose Citric Acid Croscarmellose Sodium Titanium Dioxide Polyvinylpyrrolidone FD&C Yellow #5 Lake FD&C Red #40 Lake FD&C Red #3 Lake FD&C Blue #1 Lake
Claims

Label Claims — Verification

Unverified All Other
Unverified Approved Health
Unverified Structure/Function
Info

Product Information

Directions for Use

Indication and Usage Ferrex 150 may be used for the dietary management of iron deficiencies.

Dosage and Administration Usual adult dosage is one or two capsules daily, or as directed by a physician or health-care provider. Do not exceed recommended dosage.

Warnings & Precautions

Do not use if blister seals are broken

Contraindications Ferrex 150 is contraindicated in patients with a known hypersensitivity to any of the components of this product.

Hemochromatosis and hemosiderosis are contraindications in the use of this dietary supplement.

Precautions This product contains FD&C Yellow No. 5 Lake (Tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 Lake (Tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

The type of anemia and the underlying cause or causes should be determined before initiating supplementation with Ferrex 150. Since the anemia may be a result of a systematic disturbance, such as a recurrent blood loss, the underlying cause or causes should be corrected if possible.

As with all oral iron preparations, Ferrex 150 should be stored out of the reach of children to protect against accidental iron poisoning.

Patients should not exceed the recommended dosage unless directed by a physician. Patients should be informed that iron products can cause dark or black stools.

Since oral iron products interfere with absorption of certain antibiotics, these products should not be taken within two hours of each other.

If pregnant, or planning to become pregnant or are currently breast-feeding please contact your physician, or health-care provider before using or continuing use.

Warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Adverse Reactions Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stool and abdominal pain. Adverse reactions with iron therapy are usually transient.

Overdosage The clinical cause of acute iron overdose can be variable. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.

Warning: Keep this and all medications out of the reach of children.

To report a serious adverse event contact: 1-800-367-3395. Warning: Reproductive harm - www.P65Warnings.ca.gov.

Formulation Notes

Ferrex 150 Polysaccharide-Iron Complex Capsules are a product of ferric iron complexed to a low molecular weight polysaccharide.

Polysaccharide-Iron Complex Capsules

Additional Information

51991-203-11

How Supplied Ferrex 150 Capsules are supplied as orange/brown capsules, imprinted “B203”. Each blister contains 10 capsules per card, 51991-203-11.

Store at 25 degrees C (77 degrees F); excursions permitted to 15 degrees - 30 degrees C (59 degrees - 86 degrees F). See USP controlled room temperature. Protect from light and moisture.

All substitutions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

Metadata

Product Details

UPC / SKU3 51991 20311 7
DSLD Entry Date2020-07-23
Product TypeMineral
FormCapsule
DSLD ID230127
Data Updated2026-04-11
Research

Research Evidence

566
Research Sources
56
Avg Quality
240
Meta Analysis
100
Clinical Trial
74
Systematic Review
71
Guideline
58
Rct
11
Cochrane Review
4
Regulatory Source
2
Other
2
Narrative Review
1
Observational
1
Openfda Safety
A Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency
Meta Analysis Nature medicine 2025 PubMed DOI
A Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women
Meta Analysis The Cochrane database of systematic reviews 2019 PubMed DOI
A Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Serum or plasma ferritin concentration as an index of iron deficiency and overload
Meta Analysis The Cochrane database of systematic reviews 2021 PubMed DOI
A Non-invasive diagnostic tests for Helicobacter pylori infection
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
Meta Analysis The Cochrane database of systematic reviews 2022 PubMed DOI
A Wheat flour fortification with iron and other micronutrients for reducing anaemia and improving iron status in populations
Meta Analysis The Cochrane database of systematic reviews 2021 PubMed DOI
A Fortification of condiments and seasonings with iron for preventing anaemia and improving health
Meta Analysis The Cochrane database of systematic reviews 2023 PubMed DOI
A Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement.
Guideline JAMA 2024 PubMed DOI
A Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: A meta-analysis and systematic review
Meta Analysis Neuroscience and biobehavioral reviews 2025 PubMed DOI
View all evidence for Iron →
Compare

Similar Products

View all Iron products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.